Just like last year, stock went down too low in fall then popped in the new year.
Looking forward to the same. There are multiple events for this to happen. $1B plus revenue coming in a year does and will continue to build a strong powerhouse of a biotech company. The new drugs in the pipeline will eventually bring sales to $2B a year and more.